Immatics (NASDAQ:IMTX) Expected to Announce Earnings of -$0.39 Per Share

Brokerages predict that Immatics (NASDAQ:IMTX) will announce earnings per share of ($0.39) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Immatics’ earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at ($0.33). Immatics posted earnings of ($0.38) per share in the same quarter last year, which indicates a negative year over year growth rate of 2.6%. The firm is expected to issue its next earnings report on Thursday, September 2nd.

On average, analysts expect that Immatics will report full-year earnings of ($1.61) per share for the current year, with EPS estimates ranging from ($1.75) to ($1.42). For the next year, analysts forecast that the company will post earnings of ($1.91) per share, with EPS estimates ranging from ($2.11) to ($1.68). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Immatics.

A number of analysts have commented on the company. SVB Leerink reiterated a “buy” rating and set a $26.00 target price on shares of Immatics in a research report on Sunday, May 23rd. Chardan Capital reissued a “buy” rating on shares of Immatics in a research note on Sunday, April 4th. Finally, Zacks Investment Research downgraded shares of Immatics from a “hold” rating to a “sell” rating in a report on Tuesday, May 25th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $19.60.

Immatics stock traded up $0.09 during midday trading on Thursday, hitting $12.43. 44,671 shares of the company’s stock were exchanged, compared to its average volume of 520,293. Immatics has a 12-month low of $8.66 and a 12-month high of $18.42. The stock has a market cap of $223.37 million, a PE ratio of -6.78 and a beta of -0.04. The business has a 50 day moving average price of $11.69.

Several institutional investors have recently added to or reduced their stakes in IMTX. Citigroup Inc. raised its position in shares of Immatics by 139.9% in the first quarter. Citigroup Inc. now owns 3,409 shares of the company’s stock valued at $38,000 after buying an additional 1,988 shares during the last quarter. LPL Financial LLC grew its stake in Immatics by 19.0% in the 4th quarter. LPL Financial LLC now owns 12,943 shares of the company’s stock worth $140,000 after acquiring an additional 2,070 shares during the period. Edmond DE Rothschild Holding S.A. acquired a new position in Immatics in the 1st quarter valued at $25,000. Squarepoint Ops LLC lifted its stake in shares of Immatics by 31.9% during the 4th quarter. Squarepoint Ops LLC now owns 27,618 shares of the company’s stock worth $298,000 after purchasing an additional 6,680 shares during the period. Finally, BlackRock Inc. acquired a new stake in shares of Immatics during the fourth quarter worth $83,000.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

See Also: What is the price-sales ratio?

Get a free copy of the Zacks research report on Immatics (IMTX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Immatics (NASDAQ:IMTX)

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with's FREE daily email newsletter.